Drug intelligence / Profile preview

Qingluo Tongmai

Development stage: Preclinical
Lead developer: Shanghai Hospital of Integrated Traditional Chinese and Western Medicine
Modality: Small Molecules
Administration: Oral

Overview

Qingluo Tongmai is a Traditional Chinese Medicine (TCM) formulation, administered in tablet form, currently under investigation for the treatment of thrombotic vasculitis and superficial phlebitis. Its name, which translates to "clearing collaterals and opening vessels," suggests a mechanism focused on improving blood circulation and resolving blockages within the vascular system, consistent with traditional Chinese medical principles for addressing conditions involving blood stasis and inflammation.

Other names: Qingluo Tongmai Tablets清络通脉片

Beyond the preview

Go deeper on Qingluo Tongmai.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qingluo Tongmai.

Explore the full profile